AstraZeneca to Develop Stem Cell Treatments
September 16, 2010
It was announced on September 13, that AstraZeneca has become the second major pharmaceutical company, after Pfizer, to collaborate with the University College of London to develop stem cells, in this case, to treat diabetic retinopathy. (Pfizer’s work with UCL is for AMD.) To read all about the new collaboration, please see my update. (Link)
You might also enjoy...
- What is the Future of Stem Cells in Treating Eye Disease?
- Embryonic Stem Cell Treatment for AMD
- NicOx Reacquires Rights to Glaucoma Drug From Pfizer
- Pfizer Ophthalmics and Bausch & Lomb Announce Co-Promotion Agreement Covering Xalatan, Alrex, Lotemax and Zylet
- Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells
Jump down to form below to submit your own comments